|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes显示文摘 | Jendle J Torffvit O Ridderstrale M | 2010 | Curr Med Res Opin2010，26，4： | 1 |
| 2 | Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbAlc and weight with low risk of hypoglycemia and high treatment satisfaction显示文摘 | Lind M Jendle J Torffvit O | 2012 | Prim Care Diabetes2012，6，1： | 1 |
| 3 | Weight loss with liraglufide, a once- daily htanan glucagon-like peptide-1 analogue for type 2 diabetes treamaent as monotheraqgy or added to mefformin, is primarily as a result of a reduction in fat tissue显示文摘 | Jendle J Nauek MA Matthews DR | 2009 | Diabetes Obes Metab2009，11，12： | 1 |
| 4 | The impact of smoking on inhaled insulin显示文摘 | HIMMELMANN A JENDLE J MELLEN A | 2003 | Diabetes Care2003，26，3： | 1 |
| 5 | Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbAlc and weight with low risk of hypoglycemia and high treatment satisfac- tion显示文摘 | Lind M Jendle J Torffvit O | 2012 | Prim Care Diabetes2012，6，1： | 1 |
| 6 | The impact of smoking on inhaled insulin显示文摘 | Himmelmann A Jendle J Mellen A | 2003 | Diabetes Care2003，26，3： | 1 |
| 7 | 显示文摘 | Jendle JH Karlberg BE Arborelius MJ | 1996 | Seand J Clin Lab Invest1996，56，3： | 1 |
| 8 | 显示文摘 | Jendle JH Karlberg BE | 1996 | J Intern Med1996，240，2： | 1 |
| 9 | Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type2 diabetes treatment as monotherapy or added to metformin,is primarily as a result of a reduction in fat tissue显示文摘 | Jendle J Nauck MA Matthews D | 2009 | Diabetes Obes Metab2009，11，5： | 1 |
| 10 | Weight loss with liraglu- tide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to mefformin, is primari- ly as a result of a reduction in fat tissue 显示文摘 | Jendle J Nauck MA Matthews DR | 2009 | Diabetes Obes Metab2009，，11： | 1 |
| 11 | Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monothe~apy or added to metformin,is primarily as a result of a reduction in fat tissue 显示文摘 | Jendle J Nauck MA Matthews DR | 2009 | Diabetes Obes Metab2009，11，12： | 1 |
| 12 | Periodontal conditions in 70- year-old women with osteopomsis显示文摘 | Lundstrom A Jendle J Stenstrom B | 2001 | Swed Dent J2001，25，3： | 1 |
| 13 | Weight loss with liraglutide, a once-dally human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue显示文摘 | Jendle J Nauck MA Matthews DR | 2009 | Diabetes Obes Metab2009，11，12： | 1 |
| 14 | Weight loss with liraglu- tide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue 显示文摘 | Jendle MA Nauck DR Matthews A | 2009 | Diabetes Obesity and Metabolism2009，11，： | 1 |
| 15 | Continuous glucose monitoring-- a study of the Enlite sensor during hypo - and hyperbaric conditions 显示文摘 | Adolfsson P Ornhagen H Jendle J | 2012 | Diabetes Technol Ther2012，14，6： | 1 |
| 16 | Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type 2 diabetestreatment as monotherapy or added to metformin,is primarily as a resultof a reduction in fat tissue显示文摘 | Jendle J Nauck MA Matthews DR | 2009 | Diabetes Obes Metab2009，11，： | 1 |
| 17 | The reduction in body weight with liraglutide, a once - daily human GLP - 1 analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat 显示文摘 | Jendle J Nauck MA Matthews D | 2008 | Diabetes2008，57，： | 1 |
| 18 | Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review 显示文摘 | Jendle J Martin SA Milicevic Z | 2012 | Expert Opin Investig Drugs2012，21，： | 1 |
| 19 | Evaluating the cost-ef- fectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands 显示文摘 | Valentine WJ Jendle J Saraheimo M | 2012 | Diabet Med2012，29，3： | 1 |
| 20 | The impact of smoking on inhaled insulin 显示文摘 | HIMMELMANN A JENDLE J MELLEN A | 2003 | Diabetes Care2003，26，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员